No industry in America is more in the crosshairs of antitrust scrutiny and enforcement than private equity firms. Private equity transactions and investments, especially in the healthcare sector, are not only subject to “traditional” antitrust enforcement review from the Federal Trade Commission (“FTC”) and Antitrust Division of the Department of Justice (collectively, the “Agencies”), but they are also receiving new levels of federal review pursuant to the Biden Administration’s
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 3.14.244.85
Please verify email or join us to access premium content!